Dynamic dose‐feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation
- 8 April 2007
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 99 (5) , 1066-1071
Abstract
OBJECTIVE: To compare the quality of permanent prostate brachytherapy (PPB) implants, dosimetric outcomes and urinary morbidity between patients with large (>50 mL) and those with smaller prostates, treated with a dynamic dose‐feedback technique as monotherapy for localized prostate cancer. PATIENTS AND METHODS: The series included patients with pre‐existing bladder outlet obstruction managed with planned transurethral resection or incision of the prostate; 155 consecutive men had PPB implants as monotherapy for localized prostate cancer using a dynamic dose‐feedback approach. Dosimetric variables assessed included the implant volume, the minimum dose to 90% of the prostate (D90), and the volumes of prostate receiving 100% and 150% of the prescribed dose as a percentage of the total volume (V100 and V150), during and after implantation. Urinary morbidity was recorded in terms of acute urinary retention (AUR), the need for surgical intervention after implantation and the American Urologic Association (AUA) symptom score at baseline, 1.5, 3, 6, 9, 12 and 18 months. RESULTS: In all, 38 patients had prostate volumes of ≥50 mL; prostate volume had no influence on any dosimetric variable assessed. Two patients with large prostates (≥50 mL) had AUR and required delayed surgery. Three patients with small prostates (130 Gy and had no incontinence. CONCLUSION: Using the dynamic feedback technique, there was no adverse dosimetric and urinary morbidity in men having PPB and with prostates of >50 mL. Likewise, there were no impediments, e.g. pubic arch interference, which precluded a favourable dosimetric implant in men with a large prostate. Large prostates should not be a contraindication to PPB and require no hormonal cytoreduction. Patients with obstructive lower urinary tract symptoms can be managed with planned transurethral prostatic surgery before implantation, without compromising implant quality or morbidity.Keywords
This publication has 35 references indexed in Scilit:
- The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapyBrachytherapy, 2006
- The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancerRadiotherapy and Oncology, 2005
- 12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- European Collaborative Group on Prostate Brachytherapy: Preliminary Report in 1175 PatientsEuropean Urology, 2004
- Toxicity and Early Biochemical Outcomes From 125Iodine Prostate Brachytherapy in the U.K.Clinical Oncology, 2004
- Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodologyBrachytherapy, 2003
- Assessment of implant quality for prostate brachytherapy—is D90 the best quality index?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATEJournal of Urology, 1998